Dr. Goy on the Importance of MRD Status in Patients With MCL

Andre Goy, MD
Published: Wednesday, Apr 04, 2018



Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the importance of achieving minimal residual disease (MRD) negativity in mantle cell lymphoma (MCL).

MRD negativity translates into improved outcomes, regardless of the presentation, complete remission or partial remission status, Mantle Cell Lymphoma International Prognostic Index, age, and regimen. The question is, “Can physicians change MRD positivity to MRD negativity?” High-dose therapy and transplant may improve outcomes, but the data from the NORDIC regimen show that the outcomes prior to transplant are worse for patients who are MRD positive, Goy says.

The regimen looked at rituximab (Rituxan) preemptively in patients who converted from MRD-negative to MRD-positive status. Though the vast majority of patients achieved MRD negativity, most of them relapsed. Although checkpoint inhibitors have not been utilized as monotherapy in MCL, combining other therapies like venetoclax (Venclexta) and immunotherapy may be a way to address MRD status, states Goy.
 
SELECTED
LANGUAGE


Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the importance of achieving minimal residual disease (MRD) negativity in mantle cell lymphoma (MCL).

MRD negativity translates into improved outcomes, regardless of the presentation, complete remission or partial remission status, Mantle Cell Lymphoma International Prognostic Index, age, and regimen. The question is, “Can physicians change MRD positivity to MRD negativity?” High-dose therapy and transplant may improve outcomes, but the data from the NORDIC regimen show that the outcomes prior to transplant are worse for patients who are MRD positive, Goy says.

The regimen looked at rituximab (Rituxan) preemptively in patients who converted from MRD-negative to MRD-positive status. Though the vast majority of patients achieved MRD negativity, most of them relapsed. Although checkpoint inhibitors have not been utilized as monotherapy in MCL, combining other therapies like venetoclax (Venclexta) and immunotherapy may be a way to address MRD status, states Goy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x